Literature DB >> 24718892

Hodgkin lymphoma after autoimmune diseases by age at diagnosis and histological subtype.

M Fallah1, X Liu2, J Ji2, A Försti3, K Sundquist2, K Hemminki3.   

Abstract

BACKGROUND: Increased risk of Hodgkin lymphoma (HL) associated with personal history of several autoimmune diseases (ADs), such as rheumatoid arthritis, systemic lupus erythematosus, sarcoidosis, and immune thrombocytopenic purpura, are known. Whether there are other HL-related ADs and whether the increased risk of HL after ADs holds across sex, age, year of diagnosis, or HL histological subtype is unclear. PATIENTS AND METHODS: We systematically analyzed the risk of HL in 878 161 Swedish patients diagnosed with 33 different ADs in 1964-2010. During ∼10-year follow-up of ADs patients, 371 incident HL cases were diagnosed.
RESULTS: Significantly increased overall standardized incidence ratio (SIR) for HL after ADs was 2.0 (95% confidence interval: 1.8-2.2); AD-specific SIRs: autoimmune hemolytic anemia 19.9 (7.2-43.6), sarcoidosis 10.3 (7.8-13.4), systemic lupus erythematosus 8.4 (5.2-12.9), immune thrombocytopenic purpura 7.0 (3.2-13.3), polyarteritis nodosa 6.6 (1.2-19.5), polymyositis/dermatomyositis 6.3 (2.0-14.9), Behcet's disease 5.6 (2.7-10.3), Sjögren's syndrome 5.0 (2.1-9.8), rheumatoid arthritis 3.2 (2.6-3.9), polymyalgia rheumatica 2.2 (1.4-3.5), and psoriasis 1.9 (1.3-2.6). Men with AD had slightly higher risk of HL (2.4, 2.0-2.7) compared with women (1.8, 1.5-2.0). Only 23% of ADs were diagnosed before age 35 years and the overall SIR for HL diagnosis before age 35 [1.4, (1.0-1.8)] was lower than that in older ages [35 ≤ age < 50: 2.1 (1.6-2.7); age ≥ 50: 2.2 (2.0-2.5)], except for sarcoidosis [age < 35: 19.3 (10.5-32.5); 35 ≤ age < 50: 10.4 (5.7-17.5); age ≥ 50: 8.4 (5.6-12.1)]. Risks of all classical HLs significantly increased after ADs: lymphocyte depletion 3.7 (1.5-7.6), lymphocyte-rich 3.7 (2.3-5.9), mixed cellularity 2.4 (1.8-3.2), and nodular sclerosis 1.7 (1.3-2.1).
CONCLUSION: Several, but not all ADs (11/33), had a positive association with all classical histological subtypes of HL. Higher risks of classical HL after polyarteritis nodosa, polymyositis/dermatomyositis, Behcet's disease, Sjögren's syndrome, polymyalgia rheumatica, and psoriasis were novel findings of this study.
© The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Hodgkin disease; Hodgkin lymphoma; autoimmune diseases; risk ratio

Mesh:

Year:  2014        PMID: 24718892     DOI: 10.1093/annonc/mdu144

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  18 in total

Review 1.  [Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].

Authors:  M J Waldner; A Strangfeld; M Aringer
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

2.  Clinical Characteristics of Sarcoidosis Patients with Self-Reported Lymphoma: A US Nationwide Registry Study.

Authors:  Bashar N Alzghoul; Yazan Zayed; Ahmad Obeidat; Bara Alzghoul; Abdallah Naser; Abdul-Rahim Shilbayeh; Ayoub Innabi; Tamara Al-Hakim; Mindy Buchanan; Borna Mehrad; Divya C Patel
Journal:  Lung       Date:  2021-10-19       Impact factor: 2.584

3.  Production of insulin antibody associated with relapsed hodgkin's lymphoma.

Authors:  Masatoshi Ikeda; Masaki Fujimura; Kentaro Kurosawa; Shunsuke Tsugawa; Yui Sakuramachi; Kiyoko Takano; Shintaro Okamura; Masako Kitatani; Futoshi Iioka; Satoru Tsujii; Yasuaki Hayashino
Journal:  Diabetol Int       Date:  2021-10-16

Review 4.  Pathogenesis, Diagnosis and Management of Polymyalgia Rheumatica.

Authors:  Dario Camellino; Andrea Giusti; Giuseppe Girasole; Gerolamo Bianchi; Christian Dejaco
Journal:  Drugs Aging       Date:  2019-11       Impact factor: 3.923

5.  Autoimmune and Atopic Disorders and Risk of Classical Hodgkin Lymphoma.

Authors:  Peter Hollander; Klaus Rostgaard; Karin E Smedby; Ellen T Chang; Rose-Marie Amini; Peter de Nully Brown; Bengt Glimelius; Hans-Olov Adami; Mads Melbye; Ingrid Glimelius; Henrik Hjalgrim
Journal:  Am J Epidemiol       Date:  2015-09-06       Impact factor: 4.897

6.  Personal history of psoriasis and risk of incident cancer among women: a population-based cohort study.

Authors:  W-Q Li; J Han; E Cho; S Wu; H Dai; M A Weinstock; A A Qureshi
Journal:  Br J Dermatol       Date:  2016-01-17       Impact factor: 9.302

Review 7.  Epidemiology and Etiology of Leukemia and Lymphoma.

Authors:  Jordan A Baeker Bispo; Paulo S Pinheiro; Erin K Kobetz
Journal:  Cold Spring Harb Perspect Med       Date:  2020-06-01       Impact factor: 5.159

8.  Polymyalgia Rheumatica Revealing a Lymphoma: A Two-Case Report.

Authors:  Frank Verhoeven; Xavier Guillot; Mickaël Chouk; Clément Prati; Daniel Wendling
Journal:  Case Rep Rheumatol       Date:  2016-08-11

Review 9.  Risk of malignancy in ankylosing spondylitis: a systematic review and meta-analysis.

Authors:  Chuiwen Deng; Wenli Li; Yunyun Fei; Yongzhe Li; Fengchun Zhang
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

10.  Relationship between ambient ultraviolet radiation and Hodgkin lymphoma subtypes in the United States.

Authors:  Emily M Bowen; Ruth M Pfeiffer; Martha S Linet; Wayne T Liu; Dennis D Weisenburger; D Michal Freedman; Elizabeth K Cahoon
Journal:  Br J Cancer       Date:  2016-02-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.